US OptionsDetailed Quotes
VOR250117P2500
- 1.55
- 0.000.00%
15min DelayClose Jan 8 16:00 ET
0.00High0.00Low
1.55Open1.55Pre Close0 Volume50 Open Interest2.50Strike Price0.00Turnover927.37%IV41.72%PremiumJan 17, 2025Expiry Date0.87Intrinsic Value100Multiplier8DDays to Expiry0.68Extrinsic Value100Contract SizeAmericanOptions Type-0.3420Delta0.1591Gamma1.05Leverage Ratio-0.0517Theta-0.0004Rho-0.36Eff Leverage0.0009Vega
Vor Biopharma Stock Discussion
Sign in to post a comment
$Vor Biopharma (VOR.US)$ Im keep loading, bit by bit.
2
2
$Vor Biopharma (VOR.US)$ Incoming 🚀🚀🚀
2
3
$Vor Biopharma (VOR.US)$ be quiet.. slow slow slowly
2
$Vor Biopharma (VOR.US)$ Its time.
1
1
$Vor Biopharma (VOR.US)$
Was watching this Friday painting a beautiful chart not sure why I didn't enter but I will likely enter Monday.
Was watching this Friday painting a beautiful chart not sure why I didn't enter but I will likely enter Monday.
2
4
$Vor Biopharma (VOR.US)$ be quiet 🤫🤫🤫
1
4
$Vor Biopharma (VOR.US)$
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
• Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant
• Trem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic window
...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
• Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant
• Trem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic window
...
2
1
$Vor Biopharma (VOR.US)$ Reuters· 1 min ago
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
1
$Vor Biopharma (VOR.US)$ 2.8 ////
2
3
example muln… yeah short companies/ sorry scam companies.
No comment yet
72576952 : im in from . o,75
小竜 OP 72576952 : Superb